Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in AXSM — Axsome Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to AXSM Full portfolio

Position in AXSM

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$62,631,257
+$15,051,620 QoQ
Shares Held
255,878
-9.1% QoQ
Ownership
0.488%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#38
of 503 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AXSM Over Time

Shares Held

Position Value (USD)

Derivatives in AXSM

reported options exposure · as of Jun 30, 2026
CallValue
$25,211,310
CallShares
103,000
PutValue
$38,257,551
PutShares
156,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. AXSM ranks #24 (1.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in AXSM

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $62,631,257 255,878
2026-06-30 $38,257,551 156,300
2026-06-30 $25,211,310 103,000
2026-03-31 $47,579,637 281,503
2026-03-31 $17,662,590 104,500
2026-03-31 $5,915,700 35,000
2025-12-31 $32,144,640 176,000
2025-12-31 $25,243,222 138,213
2025-12-31 $14,574,672 79,800
2025-09-30 $12,861,555 105,900
2025-09-30 $19,238,408 158,406
2025-09-30 $11,015,515 90,700
2025-06-30 $10,157,147 97,300
2025-06-30 $10,699,975 102,500
2025-06-30 $1,421,583 13,618
2025-03-31 $10,834,927 92,900
2025-03-31 $11,907,923 102,100
2025-03-31 $9,771,960 83,786
2024-12-31 $41,914,862 495,389
2024-12-31 $18,292,682 216,200
2024-12-31 $10,449,335 123,500
2024-09-30 $12,473,956 138,800
2024-09-30 $7,261,496 80,800
2024-09-30 $27,381,770 304,682
2024-06-30 $6,005,300 74,600
2024-06-30 $6,560,750 81,500
2024-06-30 $60,635,578 753,237
2024-03-31 $6,599,460 82,700
2024-03-31 $6,096,720 76,400
2024-03-31 $91,262,790 1,143,644
2023-12-31 $8,826,531 110,900
2023-12-31 $86,680,274 1,089,085
2023-12-31 $7,218,813 90,700
2023-09-30 $5,710,013 81,700
2023-09-30 $90,551,160 1,295,624
2023-09-30 $6,562,671 93,900
2023-06-30 $10,319,096 143,600
2023-06-30 $32,647,290 454,318
2023-06-30 $17,821,280 248,000
2023-03-31 $12,275,614 199,021
2023-03-31 $13,057,656 211,700
2023-03-31 $9,548,064 154,800
2022-12-31 $53,188,848 689,600
2022-12-31 $28,055,343 363,741
2022-12-31 $37,361,772 484,400
2022-09-30 $26,883,550 602,500
2022-09-30 $23,708,256 531,337
2022-09-30 $37,204,156 833,800
2022-06-30 $16,327,290 426,300
2022-06-30 $17,273,108 450,995

Report a Problem

Category
Description
Email (optional, for follow-up)